Eye Drops Manufacturing Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Eye drops manufacturing sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹12.8 crore - ₹233 crore CapEx this DPR captures:

• NABH / NABL accreditation if the project includes a clinical or diagnostic arm
• Manufacturing licence under the Drugs and Cosmetics Act 1940 (Form 25/28/28A by category)
• CDSCO + State Drug Controller dual approval for new formulations
• WHO-GMP and Schedule M revised standards compliance
• Plant Master File (PMF) and Site Master File (SMF) for export dossier
• NABL accreditation for QC lab, BSL-2/BSL-3 containment certification where applicable
• Bio-medical waste authorisation under BMW Rules 2016

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

<p>The Indian ophthalmic pharmaceutical sector encompasses a diversified product mix including anti-glaucoma, dry eye, infection, antibiotic, and anti-allergic eye drops, serving a domestic patient base supported by rising prevalence of ocular disorders. The broader Indian ophthalmic drugs market was valued at USD 1.3 billion and projected to reach USD 1.8 billion at a CAGR of 6.8% according to Market Scope data. More narrowly scoped, the India eye drop market alone was valued at USD 219.9 million in 2025 per IMARC Group, while TechSci Research pegged it at USD 500.07 million in 2024, with the divergence attributable to differing definitional scopes.

The sector also intersects with the eye drop packaging market, valued at USD 121.82 million in 2025 and projected at a CAGR of 7.98% from 2026 to 2034, indicating a supportive ancillary supply chain.</p><p>Demand drivers are structurally strong. Aging demographics constitute a primary tailwind: the population aged 60 and above in India is estimated to reach 13.2% by 2031 and 19% by 2050 per TechSci Research (2024), and this cohort is highly susceptible to age-related ocular disorders including glaucoma, cataracts, and age-related macular degeneration. Over 6.5 million cataract surgeries are conducted annually in India, each requiring post-operative eye drop regimens, generating consistent baseline demand.

Chronic disease prevalence is also rising, with systemic conditions such as diabetes contributing to diabetic retinopathy and associated pharmaceutical demand. Approximately 17.7% of the U.S. population was aged 65 and above in 2023, a useful global comparator underscoring the secular demand trend now materializing in India.</p><p>Domestic market dynamics are characterized by over 70% to 80% domestic manufacturer dominance, limiting import dependency and creating a favorable environment for domestic capacity expansion. The sector also benefits from India's position as the largest global exporter of eye drops, with recorded export shipments exceeding 17,453 across international trade databases, confirming that a well-execured manufacturing plant can serve both domestic and international markets.

Key export destinations span established pharmaceutical markets, leveraging India's cost-competitive manufacturing base and regulatory credibility.</p>

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

<p>Manufacturing technology for eye drops has evolved significantly, with Blow-Fill-Seal (BFS) Technology representing the industry standard for single-dose, preservative-free eye drop production. The BFS process is a fully automated, continuous operation in which medical-grade plastic is extruded, the container is molded, the sterile ophthalmic solution is filled, and the unit is hermetically sealed without human intervention, eliminating contamination risk at the fill-seal stage. This technology is especially critical for preservative-free formulations where sterility assurance is paramount.</p><p>The global eye drop production line market was valued at USD 7.88 billion in 2025 and is projected to reach USD 14.42 billion by 2034 at a CAGR of 6.8%, reflecting sustained capital investment in manufacturing line technology.

Capital investment varies significantly by automation level: automatic production lines operating at 200-600 units per minute require substantially higher upfront capital compared to semi-automated lines. Small-scale or basic domestic units with semi-automated lines can be established with INR 1 crore to INR 5 crores, while WHO-GMP certified mid-scale facilities with automated liquid filling lines, specialized aseptic cleanrooms, and full validation infrastructure require INR 10 crores to INR 50 crores in capital expenditure.</p><p>Process architecture for modern eye drop plants incorporates aseptic processing methods, sterile aqueous bases, and precisely calibrated preservative systems. Aseptic processing technicians are trained in sterile gowning qualification, ISO 5 cleanroom standards, and contamination control protocols.

Pharmaceutical engineers and validation specialists are responsible for maintaining environmental conditions, process validation, and batch release documentation. The workforce composition for a mid-scale facility includes core skilled roles in aseptic operations, quality control, and regulatory compliance.</p><p>Quality and compliance infrastructure includes ISO 9001 and ISO 14001 certifications. Alcon demonstrated leadership in environmental manufacturing standards in 2023 by reducing greenhouse gas emissions to 233,482 kg CO2 equivalents (down from 309,083 kg CO2 equivalents in 2021) and diverting 95.9% of annual waste from manufacturing site landfills, with a target to eliminate 100% of non-hazardous waste by 2030.

Glaukos maintained ISO 14001 Certification in 2023, reflecting the broader industry trend toward environmental compliance alongside product quality standards.</p>

For a eye drops manufacturing project at ₹12.8 crore - ₹233 crore CapEx with a 3.6 - 6.2-year payback, the bank-loan-ready Means of Finance KAMRIT recommends is 30-40% promoter equity and 60-70% debt. The primary lender pool for this scale is SBI MSME, Bank of Baroda, HDFC Bank, ICICI Bank, Axis Bank term loans plus working capital facilities. The applicable overlay schemes that materially compress effective cost-of-capital are CGTMSE up to ₹5 cr, PLI sector overlay where eligible, state capital subsidy. The Tier 2 Bankable DPR includes the full vendor-quote-backed CapEx schedule, OpEx model, 5-year revenue projection split by SKU and channel, working-capital cycle, ROI/NPV/IRR, break-even, and sensitivity in three scenarios (base / bull / bear). The model is structured for direct submission to a commercial bank or NBFC credit appraisal team.

<p>Sterility assurance failures represent the most acute operational risk in eye drops manufacturing. The sector has experienced significant product recalls in recent years, underscoring the zero-tolerance nature of aseptic processing standards. In March 2026, K.C.

Pharmaceuticals recalled 3,111,072 bottles of over-the-counter eye drops due to sterility assurance failures. In September 2024, Allergan recalled over 3 million tubes of Refresh products due to packaging seal breaches. In December 2024, Alcon initiated a recall, reinforcing that even well-capitalized, globally regulated manufacturers are not immune to quality failures.

These incidents carry consequences ranging from brand damage and regulatory sanctions to civil liability and market access restrictions.</p><p>Regulatory compliance risk is substantial and multi-layered. The revised Schedule M under the Drugs and Cosmetics Rules, 1945 became binding on January 1, 2026, introducing updated manufacturing practice requirements that facilities must continuously satisfy. CDSCO, operating under the Ministry of Health and Family Welfare, retains authority to suspend or revoke manufacturing licenses for non-compliance.

Facilities must maintain WHO-GMP certification, ISO 9001:2015 compliance, and for aseptic operations, ISO 5 cleanroom standards with qualified personnel in sterile processing techniques. Regulatory inspections, product recalls, and compliance documentation requirements impose ongoing operational costs and management attention.</p><p>Margin compression affects even established players. LSL Pharma Group Inc. reported an EBITDA margin decline from 14% in 2024 to 10% in 2026, attributed to changes in revenue mix and higher SG&A costs.

Makers Laboratories Limited reported a PBILDT margin of 1.46% in FY24 compared to 3.25% in FY23, a nearly 55% decline year-on-year. These figures illustrate that the sector can experience significant margin pressure from input cost inflation, pricing competition, and regulatory compliance cost escalation.</p><p>Substitutes and competitive alternatives pose demand-side risks. Direct drug delivery alternatives include ophthalmic inserts, punctal plugs, intraocular implants, and hydrogel lenses.

Surgical and procedural alternatives such as laser trabeculoplasty, minimally invasive glaucoma surgery (MIGS), LASIK, and cataract surgery can reduce or eliminate the need for chronic eye drop therapy in certain patient populations. Non-product substitutes including lifestyle modifications, warm compresses, tear duct occlusion, and environmental adjustments can also reduce pharmaceutical demand for mild ocular conditions.</p><p>Capital intensity and project execution risk must be carefully managed. Capital expenditure for a mid-scale WHO-GMP certified facility ranges from INR 10 crores to INR 50 crores, with additional costs for automated liquid filling lines, aseptic cleanroom construction, validation, and regulatory licensing.

Small-scale units at INR 1-5 crores carry different risk profiles, with semi-automated lines potentially facing challenges in achieving the sterility assurance required for international market access. Supply chain infrastructure requirements including specialized cold chain logistics for sterile products, storage under controlled conditions, and management of preservative-sensitive formulations add ongoing operational complexity.</p>